Certa’s FT011 granted orphan drug status in Europe for SSc
The European Medicines Agency (EMA) has granted orphan drug status to FT011, an oral therapy candidate that Certa Therapeutics is developing for systemic sclerosis (SSc). The U.S. Food and Drug Administration (FDA) awarded the therapy a similar status last year, followed by fast track designation this year.